There is nothing more toxic to shareholders than a

There is nothing more toxic to shareholders than a poster that pretends to know it all but is in fact just a smart-ass that continually speaks from his butthole.

Quote:

---

What happened to the ROTH conference? nothing manifested,..nothing ! which is why in their most recent filing they specified that they 'had no ongoing talks or negotiations' with interested parties or investors.

---

What the aforementioned poster fails to comprehend is that the 2019 ROTH conference was held during March 17-19. Regardless of the outcome of the conference it would have been too soon to report it in the 10-K filed on April 1, 2019. Not to mention that the 10-K report is for the fiscal year ended December 31, 2018.

Furthermore a poster that has a penchant for spewing garbage out of you know where, seldom gives specific reference as to exactly where the “quote” came from and its context. The poster also fails to understand that every company has an obligation not only to tell the truth, it also has an obligation to point out “Risk Factors” and to be cautious about forward looking statements. Look at any 10-K and it will be readily obvious that over 50% of the pages, are specifically written to address their SEC obligations. They are written in such a way as to scare the heck out of most investors, especially if they are taken literally. Fact is that there is always an element of risk with any investment, especially with an R&D company that is relatively speaking still at the early stages.

Here is the December 31, 2018 10-K filed on April 1, 2019

https://www.marketwatch.com/investing/Stock/o...amp;type=1

The following quote is from the first paragraph on page 55.

Quote:

---

Outlook

According to management estimates, our liquidity resources as of December 31, 2018 will not be sufficient to maintain our planned level of operations at least through March 31, 2020. We will need to seek additional capital for the purpose of implementing our business strategy and managing our business and developing drugs. Conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. We have not yet generated any revenues from its current operations, and therefore are dependent upon external sources for financing our operations. We will require significant additional financing in the near future. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements as well as the ability to obtain financing will depend on many factors, including those listed under “RISK FACTORS” beginning on page 25 of this Form 10-K. As of December 31, 2018, we have an accumulated deficit of $27.2 million. In addition, in each of the years ended December 31, 2017 and 2018, we reported losses and negative cash flows from operating activities.

We currently have no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit, or any other sources. Until we can generate significant continuing revenues, we expect to satisfy its future cash needs through debt or equity financings, or by out-licensing its distribution rights. We cannot be certain that additional funding will be available to it on acceptable terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its development and commercialization efforts.

We address our liquidity issues by implementing initiatives to raise additional funds as well as other measures that it believes will allow it to continue as a going concern.

---

Let’s focus on the last sentence, and see what initiatives the company comes up with. If they don't and remain silent, then we'll have no choice but to re-evaluate the situation.